# Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

> **NCT02883049** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 5949 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
- Central Nervous System Leukemia
- Testicular Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dasatinib
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **DRUG:** Hydrocortisone Sodium Succinate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Pegaspargase
- **DRUG:** Prednisone
- **RADIATION:** Radiation Therapy
- **DRUG:** Thioguanine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02883049
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-02-29
- **Primary completion:** 2022-12-31
- **Final completion:** 2026-10-03
- **Target enrollment:** 5949 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883049, "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02883049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*